Issei Saeki

Ube, 7558505, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Factors Affecting Temporal Changes in Ablated Liver Volume After Radiofrequency Ablation for Hepatocellular Carcinoma Evaluated by Three-Dimensional Volumetric Computed Tomography.

Factors Affecting Temporal Changes in Ablated Liver Volume After Radiofrequency Ablation for Hepatocellular Carcinoma Evaluated by Three-Dimensional Volumetric Computed Tomography.

Journal: Tomography (Ann Arbor, Mich.)

Published: July 09, 2026

Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.

Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.

Journal: Clinical nutrition ESPEN

Published: June 13, 2026

Response to 'Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child-Pugh B Hepatocellular Carcinoma'.

Response to 'Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child-Pugh B Hepatocellular Carcinoma'.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 20, 2026

A Novel Diagnostic Approach for Hepatocellular Carcinoma Using Glycosylated Ferritin.

A Novel Diagnostic Approach for Hepatocellular Carcinoma Using Glycosylated Ferritin.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: December 18, 2025

Development of a novel scoring system to determine the optimal timing of esophagogastroduodenoscopy following portosystemic shunt occlusion.

Development of a novel scoring system to determine the optimal timing of esophagogastroduodenoscopy following portosystemic shunt occlusion.

Journal: PloS one

Published: October 21, 2025

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 13, 2025

Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma.

Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: July 09, 2025

Caution Regarding Short-Term Increases in Ammonia Levels Following Splenic Artery Embolization.

Caution Regarding Short-Term Increases in Ammonia Levels Following Splenic Artery Embolization.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: June 18, 2025

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 27, 2025

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Journal: Journal of gastroenterology and hepatology

Published: May 18, 2025

A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma.

A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 18, 2025

Reply to the Letter regarding "Combination Assay of Methylated HOXA1 with Tumor Markers for Detection of Early-Stage Hepatocellular Carcinoma".

Reply to the Letter regarding "Combination Assay of Methylated HOXA1 with Tumor Markers for Detection of Early-Stage Hepatocellular Carcinoma".

Journal: Liver cancer

Published: March 14, 2025

Showing 1-12 of 67

Last Updated: 09/26/2026